IL-1B signaling is required for LCWE-induced KD vasculitis, and blocking the NLRP3/IL-1 pathway in mice, either genetically by targeting the Nlrp3, Il1b, or Il1 receptor genes, or pharmacologically using anakinra, IL-1 neutralizing antibodies, or NLRP3 small-molecule inhibitors, reduces the development of LCWE-induced cardiovascular lesions (7, 45–47). Here, IL1B is linked to vasculitis.